Goldman Sachs’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-57,100
| Closed | -$1.23M | – | 6949 |
|
|
2025
Q4 | $1.23M | Hold |
57,100
| – | – | ﹤0.01% | 4976 |
|
|
2025
Q3 | $1.1M | Hold |
57,100
| – | – | ﹤0.01% | 4969 |
|
|
2025
Q2 | $976K | Hold |
57,100
| – | – | ﹤0.01% | 4725 |
|
|
2025
Q1 | $3.64M | Sell |
57,100
-50,000
| -47% | -$5.26M | ﹤0.01% | 3652 |
|
|
2024
Q4 | $13M | Buy |
107,100
+22,000
| +26% | +$2.7M | ﹤0.01% | 2552 |
|
|
2024
Q3 | $10.6M | Buy |
+85,100
| New | +$11.8M | ﹤0.01% | 2648 |
|
|
2023
Q2 | – | Sell |
-165,400
| Closed | -$22.8M | – | 6050 |
|
|
2023
Q1 | $22.8M | Buy |
165,400
+141,900
| +604% | +$18.4M | 0.01% | 1703 |
|
|
2022
Q4 | $3.05M | Buy |
+23,500
| New | +$2.72M | ﹤0.01% | 3603 |
|
|
2022
Q3 | – | Sell |
-40,800
| Closed | -$3.06M | – | 6524 |
|
|
2022
Q2 | $3.06M | Buy |
+40,800
| New | +$3M | ﹤0.01% | 3653 |
|
|
2022
Q1 | – | Sell |
-22,600
| Closed | -$2.04M | – | 6894 |
|
|
2021
Q4 | $2.04M | Hold |
22,600
| – | – | ﹤0.01% | 4233 |
|
|
2021
Q3 | $2.09M | Hold |
22,600
| – | – | ﹤0.01% | 4165 |
|
|
2021
Q2 | $1.76M | Sell |
22,600
-51,100
| -69% | -$3.87M | ﹤0.01% | 4327 |
|
|
2021
Q1 | $5.49M | Sell |
73,700
-295,500
| -80% | -$27.3M | ﹤0.01% | 3051 |
|
|
2020
Q4 | $62.9M | Buy |
369,200
+33,500
| +10% | +$4.96M | 0.02% | 941 |
|
|
2020
Q3 | $47.1M | Buy |
335,700
+2,300
| +0.7% | +$350K | 0.01% | 1048 |
|
|
2020
Q2 | $53.5M | Sell |
333,400
-141,000
| -30% | -$19.2M | 0.02% | 903 |
|
|
2020
Q1 | $46.4M | Buy |
474,400
+17,900
| +4% | +$2.05M | 0.02% | 920 |
|
|
2019
Q4 | $58.9M | Buy |
456,500
+42,900
| +10% | +$4.33M | 0.02% | 1027 |
|
|
2019
Q3 | $31.2M | Buy |
413,600
+105,700
| +34% | +$12.5M | 0.01% | 1448 |
|
|
2019
Q2 | $46.8M | Buy |
307,900
+19,000
| +7% | +$2.31M | 0.01% | 1183 |
|
|
2019
Q1 | $34.4M | Buy |
288,900
+258,900
| +863% | +$33.3M | 0.01% | 1419 |
|
|
2018
Q4 | $3.27M | Sell |
30,000
-8,700
| -22% | -$1.09M | ﹤0.01% | 3217 |
|
|
2018
Q3 | $6.25M | Buy |
38,700
+8,700
| +29% | +$1.19M | ﹤0.01% | 2810 |
|
|
2018
Q2 | $3.96M | Buy |
+30,000
| New | +$2.83M | ﹤0.01% | 3121 |
|
|
2018
Q1 | – | Sell |
-11,000
| Closed | -$612K | – | 6373 |
|
|
2017
Q4 | $612K | Sell |
11,000
-338,000
| -97% | -$17.9M | ﹤0.01% | 4669 |
|
|
2017
Q3 | $15.8M | Buy |
349,000
+330,000
| +1,737% | +$13.2M | ﹤0.01% | 2186 |
|
|
2017
Q2 | $640K | Sell |
19,000
-85,000
| -82% | -$2.77M | ﹤0.01% | 4874 |
|
|
2017
Q1 | $3.08M | Buy |
104,000
+53,300
| +105% | +$1.65M | ﹤0.01% | 3343 |
|
|
2016
Q4 | $1.39M | Sell |
50,700
-1,500
| -3% | -$60.2K | ﹤0.01% | 4173 |
|
|
2016
Q3 | $3.21M | Sell |
52,200
-332,600
| -86% | -$10.1M | ﹤0.01% | 3416 |
|
|
2016
Q2 | $7.34M | Buy |
384,800
+174,800
| +83% | +$3.24M | ﹤0.01% | 2564 |
|
|
2016
Q1 | $4.1M | Buy |
210,000
+160,000
| +320% | +$2.8M | ﹤0.01% | 2863 |
|
|
2015
Q4 | $1.93M | Buy |
+50,000
| New | +$1.62M | ﹤0.01% | 3664 |
|
|
2014
Q3 | – | Sell |
-15,300
| Closed | -$456K | – | 7252 |
|
|
2014
Q2 | $456K | Sell |
15,300
-700
| -4% | -$22.1K | ﹤0.01% | 5402 |
|
|
2014
Q1 | $384K | Buy |
+16,000
| New | +$408K | ﹤0.01% | 5527 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Goldman Sachs's SRPT Position: Q1 2026 in Review
Goldman Sachs increased its Sarepta Therapeutics (SRPT) stake by 91% in Q1 2026, buying an estimated $9.96M and bringing the position to 1,078,252 shares worth $23.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2286.
Goldman Sachs first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $201M in Q2 2020. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Goldman Sachs held 1,078,252 shares of Sarepta Therapeutics worth $23.5M as of Q1 2026.
- Goldman Sachs bought 514,766 Sarepta Therapeutics shares in Q1 2026, an estimated $9.96M.
- Sarepta Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2286 holding.
- Goldman Sachs first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Sarepta Therapeutics position peaked at $201M in Q2 2020.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.